Generics (UK) Ltd v Yeda Research and Development Company Ltd (No 2)
| Jurisdiction | England & Wales |
| Year | 2013 |
| Date | 2013 |
| Court | Court of Appeal (Civil Division) |
-
- This document is available in original version only for vLex customers
View this document and try vLex for 7 days - TRY VLEX
- This document is available in original version only for vLex customers
5 cases
-
Sandoz Ltd v Bristol-Myers Squibb Holdings Ireland Unlimited Company
...to justify a conclusion that his patent will work.” 29 In Generics (UK) Ltd v Yeda Research & Development Co Ltd [2013] EWCA Civ 925, [2014] RPC 4 the patent concerned an improved composition of a synthetic mixture of polypeptides known as copolymer-1. Mylan attacked the validity of the pa......
-
Idenix Pharmaceuticals, Inc. v Gilead Sciences, Inc. and Others
...then, the matter has been considered by the Court of Appeal in Generics (UK) Ltd v Yeda Research & Development Co Ltd [2013] EWCA Civ 925, [2014] RPC 4, where Floyd LJ said at [39]: "As with any consideration of obviousness, the technical results or effects must be shared by everything fall......
-
Akebia Therapeutics Inc. v Fibrogen, Inc.
...then the claim is insufficient.” That statement of the law was approved by the Court of Appeal in the same case: [2013] EWCA Civ 925, [2014] RPC 4 at [78] (Floyd 401 In Anan Kasei Co. Ltd v Neo Chemicals and Oxides Ltd [2019] EWCA Civ 1646, [2020] FSR 8 at [24]–[25] (Floyd LJ) and [101]–[......
-
Generics (U.K.) Ltd trading as Mylan and Another v Yeda Research and Development Company Ltd Teva Pharmaceutical Industries Ltd (Third Party)
...a declaration of non-infringement ( [2012] EWHC 18438 (Pat)) and the Court of Appeal dismissed Mylan's appeal ( [2013] EWCA Civ 925, [2014] RPC 4). 888 expired on 23 May 2015. 3 The second round concerned European Patents (UK) Nos. 2 177 528 and 2 361 924 ("924"), which concerned improved ......
Request a trial to view additional results